Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Twist Bioscience Corp (TWST) vs Zscaler Inc (ZS) Price & Performance

Twist Bioscience CorpTrade
Zscaler IncTrade

Price performance (Past 24H)

Key statistics

Twist Bioscience Corp vs Zscaler Inc — how do they compare? Twist Bioscience Corp trades at $125.17 (market cap $7.72B), while Zscaler Inc trades at $177 (market cap $28.87B). The key difference: Zscaler Inc is far larger — about 3.7× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.

TWSTZS
Market Cap
$7.72B$28.87B
Sector
HealthTechnology
52-Week High
$124.88$336.27
52-Week Low
$24.16$118.05
Enterprise Value
$7.65B$27.20B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.

Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.

Zscaler Inc

Zscaler (ZS) trades at $176.94, up 0.15% with strong bullish technical signals and positive analyst sentiment. The stock shows consistent revenue growth from $1.1B in 2022 to $2.67B in 2025, though it remains unprofitable with a -2.44% net margin. Recent earnings beats and leadership in Gartner Magic Quadrant for SASE platforms highlight operational strength. Current price sits near resistance at $177 with RSI indicating overbought conditions.

Outlook remains positive with 79% analyst buy ratings and $191.81 consensus target, but risks include negative profitability, high valuation multiples (P/S 8.94), and projected negative cash flow in 2026. The cybersecurity leader benefits from AI-driven security demand but faces execution risks amid competitive pressures.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST

About Zscaler Inc

Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.

Read more on ZS